Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025
A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Centre for Disease Prevention and Control
2025-08-01
|
| Series: | Eurosurveillance |
| Subjects: | |
| Online Access: | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.32.2500543 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849405281775124480 |
|---|---|
| author | J Erin Staples |
| author_facet | J Erin Staples |
| author_sort | J Erin Staples |
| collection | DOAJ |
| description | A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025. |
| format | Article |
| id | doaj-art-d07bad46a09e41b1a4b597f18ba79b07 |
| institution | Kabale University |
| issn | 1560-7917 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | European Centre for Disease Prevention and Control |
| record_format | Article |
| series | Eurosurveillance |
| spelling | doaj-art-d07bad46a09e41b1a4b597f18ba79b072025-08-20T03:36:42ZengEuropean Centre for Disease Prevention and ControlEurosurveillance1560-79172025-08-01303210.2807/1560-7917.ES.2025.30.32.2500543http://instance.metastore.ingenta.com/content/eurosurveillance/30/32Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025J Erin Staples0Centers for Disease Control and Prevention, Fort Collins, Colorado, United StatesA live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025.https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.32.2500543chikungunyaseriousvaccineimmunisationixchiqlive attenuated |
| spellingShingle | J Erin Staples Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025 Eurosurveillance chikungunya serious vaccine immunisation ixchiq live attenuated |
| title | Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025 |
| title_full | Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025 |
| title_fullStr | Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025 |
| title_full_unstemmed | Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025 |
| title_short | Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025 |
| title_sort | surveillance for adverse events following use of live attenuated chikungunya vaccine united states 2024 and the associated public health response in 2024 and 2025 |
| topic | chikungunya serious vaccine immunisation ixchiq live attenuated |
| url | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.32.2500543 |
| work_keys_str_mv | AT jerinstaples surveillanceforadverseeventsfollowinguseofliveattenuatedchikungunyavaccineunitedstates2024andtheassociatedpublichealthresponsein2024and2025 |